logo

For the Inventor, By the Inventor

Al-Ahsa, Saudi Arabia

Rashmi Venugopala

This inventor holds 4 USPTO granted patents. Top assignee: King Faisal University. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rashmi Venugopala. Retrieved from https://idiyas.com/inventor/rashmi-venugopala-l4kdsbz2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4

% Patents Active = 100.0

Average Co-Inventor Count = 6.3

ph-index = 1


Company Filing History:

goldMedal4 out of 820 
 
King Faisal University
 patents

Years Active: 2024

Loading Chart...
4 patents (USPTO):Explore Patents
1. 11981674 - 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as larvicidal agents (2024-05-14),
2. 11981673 - 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7 tricarboxylates as adenosine receptor active compounds (2024-05-14),
3. 11970489 - 4-[(substituted 1H-benzimidazol-2-ylsulfanyl)methyl]-6-substituted-2H-chromen-2-ones as larvicidal agents (2024-04-30),
4. 11939294 - 1-(2-(substituted phenyl)-2-oxoethyl)-3,5-dimethylpyridin-1-ium bromides as antitubercular agents (2024-03-26),

Title: Rashmi Venugopala: Innovator in Pharmaceutical Compounds

Introduction

Rashmi Venugopala is a distinguished inventor based in Al-Ahsa, Saudi Arabia. She has made significant contributions to the field of pharmaceutical compounds, holding a total of four patents. Her work focuses on developing innovative solutions for treating various health conditions.

Latest Patents

Rashmi's latest patents include the development of 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as larvicidal agents. These compounds are particularly aimed at treating and preventing malaria. Additionally, she has patented 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7-tricarboxylates, which serve as adenosine receptor active compounds. These compounds are recognized for their potential in anti-inflammation, anticancer, and anti-ischemic applications, as well as treating conditions related to adenosine overexpression.

Career Highlights

Rashmi is currently affiliated with King Fahd University of Petroleum and Minerals, where she continues her research and development in pharmaceutical sciences. Her innovative work has positioned her as a key figure in her field, contributing to advancements in medical treatments.

Collaborations

Rashmi collaborates with notable colleagues, including Katharigatta N Venugopala and Osama I Alwassil. These partnerships enhance her research efforts and broaden the impact of her inventions.

Conclusion

Rashmi Venugopala's contributions to pharmaceutical compounds demonstrate her commitment to innovation and improving health outcomes. Her patents reflect her expertise and dedication to addressing critical health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…